AOAkishi Ooi

Akishi Ooi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akishi Ooi has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Yoh Dobashi

    Department of Pathology, Saitama Medical Center, Jichi Medical University, Saitama, 330-8503, Japan

    9 shared publications
  • Hiroko Ikeda

    Pathology Section, University Hospital, Kanazawa University, Ishikawa 920-8641, Japan

    5 shared publications
  • Takeru Oyama

    Department of Molecular and Cellular Pathology, Kanazawa University, Ishikawa 920-8641, Japan

    5 shared publications
  • Ritsuko Nakamura

    Department of Molecular and Cellular Pathology, Kanazawa University, Ishikawa 920-8641, Japan

    4 shared publications
  • Ryosuke Tajiri

    Department of Molecular and Cellular Pathology, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan

    4 shared publications
  • Hiroko Kawashima

    Section of Breast Oncology, University Hospital, Kanazawa University, Ishikawa 920-8641, Japan

    3 shared publications

Latest Publications

  • Amplicons in breast cancers analyzed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

    by Akishi Ooi, Masafumi Inokuchi, Shin-Ichi Horike, Hiroko Kawashima, Satoko Ishikawa, Hiroko Ikeda, Ritsuko Nakamura, Takeru Oyama, Yoh Dobashi


  • A Case of Peptide YY–Secreting Neuroendocrine Tumor of the Rectum Associated with Severe Constipation

    by Shohei Miyanaga, Eisuke Ojima, Yoshio Michiwa, Tatsuo Nakano, Kotaro Higashi, Hiroto Nishida, Kayo Nishi, Akishi Ooi

    A 30-year-old woman was referred because of increasingly severe constipation and a left para-ovarian tumor. She presented initially at 25 years of age because of nausea during menses, and a tumor near the left ovary was found. Abdominal computed tomography showed severe inhibition of bowel motility and a tumor (70 × 30 mm) near the left ovary. On colorectal endoscopy, a submucosal tumor was found in the rectum, 6 cm from the anal verge, and a biopsy showed carcinoid tumor. Transanal resection of the rectal tumor and simple resection of the para-ovarian tumor were performed. The 1.2-cm-diameter rectal tumor in the mucosa and submucosa showed the typical histology of a carcinoid tumor. On immunohistochemistry, approximately 70% of tumor cells were peptide YY (PYY) positive, and Ki-67–positive nuclei accounted for less than 1%. The para-ovarian mass was an encapsulated solid tumor measuring 65 × 35 × 30 mm, and was histologically and immunohistochemically similar to the rectal tumor. Serum PYY was more than 8 times higher than that of control subjects preoperatively; it fell to half postoperatively, and her symptoms subsided. However, 111In-pentreotide scintigraphy showed somatostatin receptor–positive tumors located near the rectum and left obturator cavity. On laparoscopy, 2 tumors, 2.5 and 1.6 cm in diameter, in the mesorectum and a 1.0-cm-diameter tumor in the obturator canal were resected. Histologically and immunohistochemically, the tumors were similar to the previously resected tumors except for the lymph node found in 1 tumor. Based on this case, severe constipation due to PYY appears to be a new carcinoid syndrome.

  • Open Access

    Gene amplification of CCNE1 , CCND1 , and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

    by Akishi Ooi, Takeru Oyama, Ritsuko Nakamura, Ryousuke Tajiri, Hiroko Ikeda, Sachio Fushida, Yoh Dobashi


  • Overexpression and gene amplification of bothERBB2andEGFRin an esophageal squamous cell carcinoma revealed by fluorescencein situhybridization, multiplex ligation-dependent probe amplification and immunohistochemistry

    by Takeru Oyama, Koichi Okamoto, Ritsuko Nakamura, Ryosuke Tajiri, Hiroko Ikeda, Itasu Ninomiya, Akishi Ooi

    EGFR and ERBB2 belong to the EGFR gene family. In esophageal squamous cell carcinomas (SCCs), amplification of EGFR or ERBB2 is usually mutually exclusive. EGFR amplification occurs in approximately 15% of SCCs, ERBB2 occurs in less than 5%. Here, we report the co-amplification of EGFR and ERBB2 in an ulcerative and infiltrating-type SCC that measured approximately 4.2 × 2.7 × 1.2cm with a superficial lesion occurring in the thoracic esophagus of a 72-year-old man. Multiplex ligation-dependent probe amplification using representative tumor sections showed gain of CCND1 and coincident amplification of ERBB2 or EGFR or neither. Immunohistochemistry and fluorescence in situ hybridization revealed that the tumor comprised three cancer-cell populations: well-differentiated SCC with high-level ERBB2 amplification and ERBB2 overexpression, more infiltrative poorly-differentiated SCC with high-level EGFR amplification and EGFR overexpression, and poorly-differentiated SCC lacking any ERBB2 or EGFR abnormality. These three populations each had low-level CCND1 amplification and nuclear cyclin D1 overexpression. This histological topology and gene amplification combinations suggested that genetic instability first produced CCND1 amplification, and then ERBB2 or EGFR gene amplification occurred. It is further speculated that during cancer progression and clonal selection indecisive predominance of either clone caused the rare co-amplification of ERBB2 and EGFR in a single chimeric tumor. © 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.発行後1年より全文公


  • Open Access

    Semi-comprehensive analysis of gene amplification in gastric cancers using multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

    by Akishi Ooi, Takeru Oyama, Ritsuko Nakamura, Ryosuke Tajiri, Hiroko Ikeda, Sachio Fushida, Hiroyuki Nakamura, Yoh Dobashi


  • Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation‐dependent probe amplification and fluorescence in situ hybridization

    by Ryosuke Tajiri, Masafumi Inokuchi, Seiko Sawada‐Kitamura, Hiroko Kawashima, Ritsuko Nakamura, Takeru Oyama, Yoh Dobashi, Akishi Ooi

    A needle biopsy of a mass in the right breast of a 36‐year‐old woman revealed invasive ductal carcinoma (IDC), and approximately 20% of cancer cells showed unequivocal membranous staining with the HercepTest. After systemic therapy with trastuzumab and paclitaxel followed by FEC (fluorouracil + epirubicin + cyclophosphamide), a right mastectomy was performed. By histological and immunohistochemical examinations, the resected tumor consisted mainly of E‐cadherin‐negative invasive lobular carcinoma (ILC), and the rest was ERBB2‐positive IDC; thus, the diagnosis was mixed ductal and lobular carcinoma. Multiplex ligation‐dependent probe amplification and fluorescence in situ hybridization (FISH) analyses revealed that ILC and IDC shared high‐level amplification of CCND1 in homogeneously staining regions (HSR) and that IDC had an additional HSR‐type amplicon of ERBB2. These findings strongly indicate that IDC and ILC had a common precursor cell with CCND1 amplification. Review of the biopsy specimen with FISH showed IDC with gene amplifications of CCND1 and ERBB2 as a minor component, IDC without amplification of CCND1 or ERBB2 as a major component, and a minute portion of ILC with CCND1 amplification. We speculate that chemotherapy and trastuzumab caused a marked reduction in IDC; however, ILC with CCND1 amplification was resistant to chemotherapy and grew.


    • 15 June 2013
      • Vol. 6  (7) , 1306-16

    Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics.

    by Hiroaki Kimura, Yoh Dobashi, Takayuki Nojima, Hiroyuki Nakamura, Norio Yamamoto, Hiroyuki Tsuchiya, Hiroko Ikeda, Seiko Sawada-Kitamura, Takeru Oyama, Akishi Ooi

    The atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDLS) and the de-differentiated liposarcoma (DDLS) represent the most common category of liposarcomas. ALT/WDLSs and DDLSs are often difficult to distinguish from other tumors with similar morphological characteristics. In this study, we investigated whether the detection of amplified or overexpressed murine double-minute 2 (MDM2) can be a useful diagnostic ancillary aid. We used fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) to detect MDM2 amplification and protein overexpression, respectively, in 49 WDLSs, 5 DDLSs, 23 myxoid liposarcomas, 25 benign lipomatous tumors, and 75 spindle and pleomorphic sarcomas. MDM2 amplification was detected in 48 of 49 WDLSs, 5 of 5 DDLSs, 2 of 9 malignant peripheral nerve sheath tumors, and 2 of 10 myxofibrosarcomas. We did not detect MDM2 amplification in any of the benign lipomatous tumors. FISH-mediated detection of MDM2 amplification was the most valuable diagnostic aid for ALT/WDLS, as determined by using the Fisher exact test to compare two different diagnoses of 19 biopsies. On the contrary, unequivocal nuclear overexpression of MDM2 was found in only 10 of 50 ALT/WDLSs. The sensitivity and specificity of MDM2 amplification in distinguishing a DDLS from spindle and pleomorphic sarcomas were 100% and 95%, respectively, while those of MDM2 overexpression were 100% and 87%, respectively. In conclusion, our results indicate that FISH-mediated detection of MDM2 amplification is the most useful adjunct in the diagnosis of both ALT/WDLS and DDLS. However, IHC-mediated detection of MDM2 protein is useful only for the diagnosis of DDLS.


  • Open Access

    LINE-1 methylation shows little intra-patient heterogeneity in primary and synchronous metastatic colorectal cancer

    by Aika Matsunoki, Kazuyuki Kawakami, Masanori Kotake, Mami Kaneko, Hirotaka Kitamura, Akishi Ooi, Go Watanabe, Toshinari Minamoto

    Background: Long interspersed nucleotide element 1 (LINE-1) hypomethylation is suggested to play a role in the progression of colorectal cancer (CRC). To assess intra-patient heterogeneity of LINE-1 methylation in CRC and to understand its biological relevance in invasion and metastasis, we evaluated the LINE-1 methylation at multiple tumor sites. In addition, the influence of stromal cell content on the measurement of LINE-1 methylation in tumor tissue was analyzed. Methods: Formalin-fixed paraffin-embedded primary tumor tissue was obtained from 48 CRC patients. Matched adjacent normal colon tissue, lymph node metastases and distant metastases were obtained from 12, 18 and 7 of these patients, respectively. Three different areas were microdissected from each primary tumor and included the tumor center and invasive front. Normal mucosal and stromal cells were also microdissected for comparison with the tumor cells. The microdissected samples were compared in LINE-1 methylation level measured by multicolor MethyLight assay. The assay results were also compared between microdissected and macrodissected tissue samples. Results: LINE-1 methylation within primary tumors showed no significant intra-tumoral heterogeneity, with the tumor center and invasive front showing identical methylation levels. Moreover, no difference in LINE-1 methylation was observed between the primary tumor and lymph node and distant metastases from the same patient. Tumor cells showed significantly less LINE-1 methylation compared to adjacent stromal and normal mucosal epithelial cells. Consequently, LINE-1 methylation was significantly lower in microdissected samples compared to macrodissected samples. A trend for less LINE-1 methylation was also observed in more advanced stages of CRC. Conclusions: LINE-1 methylation shows little intra-patient tumor heterogeneity, indicating the suitability of its use for molecular diagnosis in CRC. The methylation is relatively stable during CRC progression, leading us to propose a new concept for the association between LINE-1 methylation and disease stage.


  • Open Access

    Gene amplification of ESR1 in breast cancers—fact or fiction? A fluorescence in situ hybridization and multiplex ligation‐dependent probe amplification study

    by Akishi Ooi, Masafumi Inokuchi, Shinichi Harada, Johji Inazawa, Ryousuke Tajiri, Seiko Sawada‐ Kitamura, Hiroko Ikeda, Hiroko Kawashima, Yoh Dobashi

    Oestrogen receptor‐alpha (ERα), encoded by the ESR1 gene located on 6q25, is a nuclear transcription factor. Since it was reported in 2007 that more than 20% of breast cancers show ESR1 gene amplification, there has been considerable controversy about its frequency and clinical significance. We set out to assess the frequency and levels of ESR1 amplification in breast cancers. In a total of 106 breast needle biopsy specimens examined by immunohistochemistry, 78 tumours contained more than 10% ERα‐positive cancer cells. In fluorescence in situ hybridization (FISH) analysis with an ESR1‐specific probe, variously extended ESR1 signals were found in ERα‐expressing cells. Some of these were indistinguishable from large clustered signals generally accepted to mean high‐level gene amplification in homogeneously staining regions (HSRs), and could be considered to represent gene amplification. However, with RNase treatment, the ‘HSR‐like’ signals changed to small compact signals, and are thus thought to represent concentrated RNA. FISH using two differently labelled probes corresponding to the non‐overlapping 5′‐ and 3′‐end portions of the ESR1 gene on touch smears showed a preserved spatial relationship of the 3′ to 5′ sequence of ESR1, therefore strongly suggesting that the RNA consisted of primary transcripts. Using touch smears obtained from 51 fresh tumours, precise enumeration of ESR1 signals with a correction by the number of centromere 6 on FISH after RNase A treatment revealed that three tumours (5.9%) had tumour cells with one to three additional copies of ESR1 as predominant subpopulations. This infrequent and low level of gene amplification of ESR1 was also detected as a ‘gain’ of the gene by analysis with multiplex ligation‐dependent probe amplification (MLPA). The consistent results from immunohistochemistry, FISH, and MLPA in the present study settle the long‐standing debate concerning gene amplification of ESR1 in breast carcinoma. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.